537697-19-1

Basic information

• Product Name: Carbamic acid, [(1R,2R)-1-(hydroxymethyl)-2-methoxypropyl]-, 1,1-
• Synonyms: Carbamic acid, [(1R,2R)-1-(hydroxymethyl)-2-methoxypropyl]-, 1,1-
• CAS NO: 537697-19-1
• Molecular Formula: C10H21NO4
• Molecular Weight: 219.27804
• Product Categories: N-BOC
• Mol File: 537697-19-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 343.6±32.0 °C(Predicted)
• Appearance: /
• Density: 1.041±0.06 g/cm3(Predicted)
• PKA: 11.60±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1R,2R)-1-(hydroxymethyl)-2-methoxypropyl]-, 1,1-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R,2R)-1-(hydroxymethyl)-2-methoxypropyl]-, 1,1-(537697-19-1)
• EPA Substance Registry System: Carbamic acid, [(1R,2R)-1-(hydroxymethyl)-2-methoxypropyl]-, 1,1-(537697-19-1)

Safety Data

• Hazardous Substances Data: 537697-19-1(Hazardous Substances Data)

Upstream product

• 48068-25-3 (2S,3R)-2-((tert-butoxycarbonyl)amino)-3-methoxybutanoic acid 
• 543-27-1 isobutyl chloroformate 
• 139374-02-0 (2R,3R)-2-(t-butoxycarbonyl)amino-1-(t-butyldimethyl)siloxy-3-butanol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1287206-15-8 tert-butyl {(2R,3R)-1-[(4-bromophenyl)amino]-3-methoxybutan-2-yl}carbamate 
• 1287206-16-9 ((1R,2R)-1-{[(4-bromophenyl)(trans-2-(pyrazin-2-yl)cyclopropanecarbonyl)amino]methyl}-2-methoxypropyl)carbamic acid tert-butyl ester 
• 1332854-67-7 C₂₃H₂₅FN₄O₄S*ClH 

Relevant articles and documents

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.